Established 2019 · Series B · AI × Biomedical
Capital for
the inflection
point.
Spidal Venture partners with Series B founders building defensible companies where artificial intelligence and biomedical science converge — and compound.
§ Thesis
The next decade of value will be created where computation meets cellular biology.
We invest at Series B — the moment a company has proven its science and product, and now needs disciplined capital to scale across markets, regulation, and infrastructure. This is where conviction is rewarded.
Our partners come from operating roles at frontier AI labs, oncology pipelines, and medical device pioneers. We bring more than capital: we bring the network that compresses the next five years of distribution into eighteen months.
Where we invest.
Foundation Models for Biology
Protein design, single-cell transcriptomics, and multi-modal models trained on proprietary lab data.
Clinical Intelligence
AI systems that augment diagnosticians, radiologists, and pathologists with regulatory-grade evidence.
Drug Discovery Platforms
End-to-end pipelines where machine learning compresses preclinical timelines by orders of magnitude.
Medical Devices & Robotics
Embedded intelligence at the point of care — surgical robotics, wearables, and decentralized trials.
§ Selected Portfolio
Founders building the durable companies of the decade.
From the partnership
"We don't chase narratives. We underwrite the founders who will still be compounding when the cycle turns."
§ Get in touch
Building
something
extraordinary?
We read every introduction. The most useful pitches arrive with a working product, a defensible insight, and a clear question.
Menlo Park · Boston · London